



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

May 2017





HIV/AIDS Drug Treatment Program

Monthly Report

© 2017 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

May 2017

N = 7226



Health Authority	Male	Female	All
FRASER	1375	400	1775
INTERIOR	372	98	470
NORTHERN	134	84	218
VANCOUVER COASTAL	3412	446	3858
VANCOUVER ISLAND	705	161	866
	5998	1189	7187
		Unknown/not stated:	39
		Total:	7226

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (May 2012 - May 2017)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (May 2012 - May 2017)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (May 2012 - May 2017)






1.5 BC-CfE Enrollment: New Antiretroviral Participants
(May 2012 - May 2017)






1.6 Percent Distribution of Active Participants by CD4 Count (May 2012 - May 2017)






1.7 Percent Distribution of Inactive Participants by CD4 Count (May 2012 - May 2017)






1.8 Active and Inactive Participants (May 2012 - May 2017)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (May 2012 - May 2017)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (May 2012 - May 2017)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(May 2012 - May 2017)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (May 2012 - May 2017)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(May 2012 - May 2017)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (May 2012 - May 2017)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(May 2012 - May 2017)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (May 2012 - May 2017)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(May 2012 - May 2017)






1.18 Baseline CD4 for Antiretroviral First Starts
(May 2012 - May 2017)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (May 2012 - May 2017)





1.20 Cumulative Resistance Testing Results by Resistance Category (May 2012 - May 2017)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (May 2012 - May 2017)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2017
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	25	5	0	5	5	630	5	<40	3
1988	25	7	0	7	7	590	7	<40	3
1989	24	57	2	59	48	480	57	<40	3
1990	23	61	1	62	56	485	62	<40	3
1991	23	37	3	40	32	565	39	<40	3
1992	23	68	6	74	59	550	72	<40	3
1993	22	144	16	160	144	540	155	<40	3
1994	21	92	12	104	93	570	102	<40	3
1995	20	122	22	144	118	555	137	<40	3
1996	18	364	60	424	366	580	407	<40	3
1997	17	291	37	328	302	610	318	<40	3
1998	16	208	42	250	214	580	232	<40	3
1999	16	175	42	217	189	540	206	<40	3
2000	16	135	38	173	151	570	164	<40	3
2001	15	130	33	163	139	590	156	<40	3
2002	14	138	32	170	145	560	162	<40	3
2003	14	169	29	198	171	590	192	<40	3
2004	13	175	38	213	179	610	200	<40	3
2005	12	194	48	242	210	610	226	<40	3
2006	11	207	48	255	213	560	243	<40	3
2007	10	277	55	332	279	590	308	<40	3
2008	9	311	70	381	319	610	360	<40	3
2009	8	341	80	421	359	630	396	<40	3
2010	7	301	74	375	313	620	350	<40	3
2011	6	353	73	426	373	670	402	<40	3
2012	5	292	62	354	305	660	335	<40	3
2013	4	280	68	348	291	650	335	<40	3
2014	3	303	58	361	298	700	336	<40	3
2015	2	324	56	380	331	650	362	<40	3
2016	1	318	68	386	336	580	381	<40	3
2017	0	136	17	153	147	538	151	<40	3
Total:		6015	1190	7205					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2016	6970	737	2262	<40	2022	590
FEB-2016	6989	735	2064	<40	1865	590
MAR-2016	6995	737	2155	<40	1958	590
APR-2016	7014	734	2053	<40	1864	580
MAY-2016	7043	747	2071	<40	1885	590
JUN-2016	7062	739	2179	<40	1991	610
JUL-2016	7052	749	1949	<40	1760	600
AUG-2016	7069	750	2068	<40	1876	590
SEP-2016	7108	752	2214	<40	1998	600
OCT-2016	7138	747	2153	<40	1935	600
NOV-2016	7169	742	2110	<40	1901	580
DEC-2016	7192	752	1872	<40	1703	620
JAN-2017	7181	748	2324	<40	2059	590
FEB-2017	7133	755	1913	<40	1712	600
MAR-2017	7187	746	2200	<40	1975	600
APR-2017	7182	748	1967	<40	1717	590
MAY-2017	7226	749	2277	<40	1925	600

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2016	1512	2278	116	<40	104	465
FEB-2016	1504	2315	83	353	74	380
MAR-2016	1511	2296	87	130	83	440
APR-2016	1515	2286	87	<50	74	360
MAY-2016	1499	2374	79	<40	69	350
JUN-2016	1510	2358	72	76	56	505
JUL-2016	1534	2309	81	<50	75	460
AUG-2016	1558	2223	94	158	78	360
SEP-2016	1545	2276	96	240	80	360
OCT-2016	1519	2449	74	<40	70	415
NOV-2016	1516	2490	73	1007	58	380
DEC-2016	1517	2511	52	122	44	480
JAN-2017	1534	2493	88	140	77	420
FEB-2017	1591	2255	80	1328	67	400
MAR-2017	1545	2445	101	635	88	370
APR-2017	1562	2408	93	517	81	420
MAY-2017	1536	2524	84	105	69	420

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2016	6940	1512	9	16	152	168	-12	12409
FEB-2016	6960	1504	5	18	178	163	20	12437
MAR-2016	6968	1511	9	24	170	173	8	12471
APR-2016	6987	1515	6	20	166	157	19	12505
MAY-2016	7018	1499	7	23	159	142	31	12536
JUN-2016	7032	1510	12	34	163	167	14	12579
JUL-2016	7015	1534	11	25	136	157	-17	12611
AUG-2016	7031	1558	10	40	165	172	16	12671
SEP-2016	7073	1545	5	27	179	151	42	12714
OCT-2016	7101	1519	11	22	161	138	28	12745
NOV-2016	7127	1516	20	27	181	160	26	12791
DEC-2016	7149	1517	11	25	154	142	22	12831
JAN-2017	7143	1534	21	22	140	145	-6	12863
FEB-2017	7105	1591	10	24	136	186	-38	12897
MAR-2017	7154	1545	17	19	189	140	49	12923
APR-2017	7150	1562	12	21	143	154	-4	12955
MAY-2017	7205	1536	7	22	174	133	55	12989

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2016	58	6405	446	61	6970	0.83%	91.89%	6.40%	0.88%	100.00%
FEB-2016	59	6436	435	59	6989	0.84%	92.09%	6.22%	0.84%	100.00%
MAR-2016	54	6442	438	61	6995	0.77%	92.09%	6.26%	0.87%	100.00%
APR-2016	54	6464	439	57	7014	0.77%	92.16%	6.26%	0.81%	100.00%
MAY-2016	57	6495	437	54	7043	0.81%	92.22%	6.20%	0.77%	100.00%
JUN-2016	60	6499	447	56	7062	0.85%	92.03%	6.33%	0.79%	100.00%
JUL-2016	57	6496	442	57	7052	0.81%	92.12%	6.27%	0.81%	100.00%
AUG-2016	57	6509	447	56	7069	0.81%	92.08%	6.32%	0.79%	100.00%
SEP-2016	58	6546	447	57	7108	0.82%	92.09%	6.29%	0.80%	100.00%
OCT-2016	58	6578	445	57	7138	0.81%	92.15%	6.23%	0.80%	100.00%
NOV-2016	61	6603	446	59	7169	0.85%	92.10%	6.22%	0.82%	100.00%
DEC-2016	62	6635	437	58	7192	0.86%	92.26%	6.08%	0.81%	100.00%
JAN-2017	61	6614	443	63	7181	0.85%	92.10%	6.17%	0.88%	100.00%
FEB-2017	60	6578	440	55	7133	0.84%	92.22%	6.17%	0.77%	100.00%
MAR-2017	60	6629	439	59	7187	0.83%	92.24%	6.11%	0.82%	100.00%
APR-2017	59	6634	430	59	7182	0.82%	92.37%	5.99%	0.82%	100.00%
MAY-2017	62	6667	438	59	7226	0.86%	92.26%	6.06%	0.82%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2016	4 19%	2818 42%	4 19%	2485 37%	0 0%	93 1%	0 0%	11 0%	0 0%	8 0%	0 0%	0 0%	17 81%	4165 62%
FEB-2016	10 36%	2851 42%	9 32%	2519 37%	1 4%	94 1%	0 0%	11 0%	0 0%	8 0%	0 0%	0 0%	18 64%	4135 61%
MAR-2016	9 26%	2877 43%	7 21%	2542 38%	1 3%	94 1%	0 0%	11 0%	0 0%	8 0%	0 0%	0 0%	26 76%	4112 61%
APR-2016	12 35%	2893 43%	9 26%	2567 38%	3 9%	93 1%	0 0%	11 0%	0 0%	8 0%	0 0%	5 0%	22 65%	4103 60%
MAY-2016	8 26%	2894 43%	8 26%	2578 38%	0 0%	92 1%	0 0%	11 0%	0 0%	7 0%	0 0%	6 0%	23 74%	4120 61%
JUN-2016	11 26%	2924 43%	11 26%	2602 38%	0 0%	91 1%	0 0%	12 0%	0 0%	7 0%	1 2%	9 0%	31 72%	4117 60%
JUL-2016	9 28%	2903 43%	9 28%	2583 38%	0 0%	90 1%	0 0%	12 0%	0 0%	7 0%	0 0%	9 0%	23 72%	4113 60%
AUG-2016	11 19%	2936 43%	11 19%	2626 38%	0 0%	80 1%	0 0%	11 0%	0 0%	7 0%	6 10%	22 0%	42 71%	4097 60%
SEP-2016	14 33%	2969 43%	12 28%	2659 39%	0 0%	81 1%	0 0%	8 0%	0 0%	6 0%	3 7%	25 0%	27 63%	4102 60%
OCT-2016	11 35%	2997 43%	11 35%	2689 39%	0 0%	82 1%	0 0%	9 0%	0 0%	7 0%	0 0%	26 0%	20 65%	4098 59%
NOV-2016	17 37%	3023 44%	17 37%	2722 39%	0 0%	78 1%	0 0%	7 0%	0 0%	6 0%	0 0%	35 1%	29 63%	4088 59%
DEC-2016	7 18%	3058 44%	7 18%	2753 40%	0 0%	77 1%	0 0%	6 0%	0 0%	6 0%	0 0%	35 1%	33 83%	4077 59%
JAN-2017	13 41%	3067 44%	13 41%	2771 40%	0 0%	75 1%	0 0%	5 0%	0 0%	6 0%	0 0%	46 1%	19 59%	4051 58%
FEB-2017	12 35%	3073 44%	10 29%	2782 40%	1 3%	71 1%	0 0%	5 0%	0 0%	6 0%	0 0%	50 1%	22 65%	3982 58%
MAR-2017	7 27%	3106 45%	7 27%	2825 41%	0 0%	69 1%	0 0%	6 0%	0 0%	5 0%	0 0%	78 1%	19 73%	4000 57%
APR-2017	13 41%	3116 45%	12 38%	2836 41%	1 3%	68 1%	0 0%	6 0%	0 0%	6 0%	0 0%	96 1%	19 59%	3964 57%
MAY-2017	9 26%	3156 45%	9 26%	2878 41%	0 0%	73 1%	0 0%	6 0%	0 0%	5 0%	1 3%	120 2%	24 71%	3934 56%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine			
	Initial		All	
JAN-2016	17	81%	3848	57%
FEB-2016	18	64%	3828	57%
MAR-2016	25	74%	3809	56%
APR-2016	22	65%	3812	56%
MAY-2016	23	74%	3834	56%
JUN-2016	32	74%	3829	56%
JUL-2016	23	72%	3830	56%
AUG-2016	48	81%	3831	56%
SEP-2016	29	67%	3847	56%
OCT-2016	20	65%	3848	56%
NOV-2016	29	63%	3852	56%
DEC-2016	33	83%	3843	55%
JAN-2017	19	59%	3828	55%
FEB-2017	22	65%	3771	55%
MAR-2017	19	73%	3803	55%
APR-2017	19	59%	3793	55%
MAY-2017	25	74%	3799	54%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2016	0 0%	11 0%	5 45%	1822 55%	5 45%	1128 34%	1 9%	326 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
FEB-2016	0 0%	10 0%	6 46%	1793 55%	6 46%	1155 35%	1 8%	317 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
MAR-2016	0 0%	9 0%	4 25%	1770 55%	11 69%	1171 36%	1 6%	300 9%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
APR-2016	0 0%	9 0%	1 7%	1747 54%	13 93%	1197 37%	0 0%	293 9%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
MAY-2016	0 0%	8 0%	2 17%	1728 53%	10 83%	1220 38%	0 0%	282 9%	0 0%	2 0%	0 0%	1 0%	0 0%	16 0%
JUN-2016	0 0%	8 0%	3 20%	1709 53%	12 80%	1235 38%	0 0%	283 9%	0 0%	4 0%	0 0%	1 0%	0 0%	15 0%
JUL-2016	0 0%	7 0%	3 21%	1689 53%	11 79%	1242 39%	0 0%	273 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
AUG-2016	0 0%	8 0%	3 10%	1663 52%	26 90%	1254 39%	0 0%	268 8%	0 0%	2 0%	0 0%	0 0%	0 0%	14 0%
SEP-2016	0 0%	8 0%	1 9%	1643 52%	9 82%	1269 40%	1 9%	262 8%	0 0%	3 0%	0 0%	1 0%	0 0%	14 0%
OCT-2016	0 0%	8 0%	2 18%	1615 51%	9 82%	1263 40%	0 0%	261 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
NOV-2016	0 0%	9 0%	3 16%	1588 51%	15 79%	1282 41%	1 5%	258 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
DEC-2016	0 0%	9 0%	3 17%	1588 50%	15 83%	1305 41%	0 0%	258 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
JAN-2017	0 0%	9 0%	2 14%	1557 50%	12 86%	1313 42%	0 0%	247 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
FEB-2017	0 0%	9 0%	3 19%	1517 49%	12 75%	1307 43%	1 6%	236 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
MAR-2017	0 0%	8 0%	1 8%	1513 49%	11 92%	1329 43%	0 0%	232 8%	0 0%	2 0%	0 0%	1 0%	0 0%	12 0%
APR-2017	0 0%	8 0%	0 0%	1483 49%	5 71%	1321 43%	2 29%	231 8%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2017	0 0%	9 0%	0 0%	1462 48%	14 100%	1349 44%	0 0%	227 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2016	0	0%	1	0%
FEB-2016	0	0%	1	0%
MAR-2016	0	0%	1	0%
APR-2016	0	0%	1	0%
MAY-2016	0	0%	1	0%
JUN-2016	0	0%	1	0%
JUL-2016	0	0%	1	0%
AUG-2016	0	0%	0	0%
SEP-2016	0	0%	1	0%
OCT-2016	0	0%	1	0%
NOV-2016	0	0%	1	0%
DEC-2016	0	0%	1	0%
JAN-2017	0	0%	1	0%
FEB-2017	0	0%	1	0%
MAR-2017	0	0%	1	0%
APR-2017	0	0%	1	0%
MAY-2017	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2016	2 100%	1032 42%	0 0%	302 12%	0 0%	855 35%	0 0%	256 10%
FEB-2016	3 60%	1008 41%	0 0%	306 13%	1 20%	857 35%	1 20%	259 11%
MAR-2016	2 50%	996 41%	0 0%	307 13%	1 25%	854 35%	1 25%	257 11%
APR-2016	3 33%	990 41%	1 11%	308 13%	3 33%	845 35%	2 22%	260 11%
MAY-2016	5 63%	986 41%	0 0%	303 13%	0 0%	834 35%	3 38%	260 11%
JUN-2016	4 67%	979 41%	0 0%	298 13%	0 0%	839 35%	2 33%	260 11%
JUL-2016	1 25%	969 41%	1 25%	299 13%	2 50%	836 35%	0 0%	257 11%
AUG-2016	5 71%	960 41%	0 0%	295 13%	0 0%	830 35%	2 29%	262 11%
SEP-2016	2 50%	949 41%	0 0%	295 13%	0 0%	819 35%	2 50%	265 11%
OCT-2016	1 20%	944 41%	2 40%	300 13%	1 20%	814 35%	1 20%	269 12%
NOV-2016	7 88%	936 41%	1 13%	294 13%	0 0%	812 35%	0 0%	269 12%
DEC-2016	7 70%	927 40%	0 0%	290 13%	0 0%	805 35%	3 30%	273 12%
JAN-2017	4 80%	928 41%	0 0%	292 13%	1 20%	799 35%	0 0%	269 12%
FEB-2017	4 80%	907 40%	0 0%	280 12%	0 0%	791 35%	1 20%	266 12%
MAR-2017	1 50%	898 40%	0 0%	279 13%	0 0%	790 35%	1 50%	265 12%
APR-2017	4 44%	889 40%	0 0%	273 12%	1 11%	787 35%	4 44%	271 12%
MAY-2017	3 75%	878 40%	0 0%	274 12%	0 0%	783 35%	1 25%	279 13%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	dolutegravir		elvitegravir		maraviroc		raltegravir		enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2016	6 55%	1020 44%	4 36%	458 20%	0 0%	66 3%	1 9%	821 35%	0 0%	1 0%
FEB-2016	7 64%	1062 45%	4 36%	468 20%	0 0%	60 3%	0 0%	813 34%	0 0%	1 0%
MAR-2016	15 79%	1115 46%	2 11%	482 20%	0 0%	60 2%	2 11%	806 33%	0 0%	1 0%
APR-2016	12 67%	1153 47%	4 22%	491 20%	0 0%	60 2%	2 11%	799 32%	0 0%	1 0%
MAY-2016	13 76%	1182 47%	4 24%	493 20%	0 0%	60 2%	0 0%	798 32%	0 0%	1 0%
JUN-2016	16 62%	1216 48%	9 35%	506 20%	0 0%	58 2%	1 4%	788 31%	0 0%	1 0%
JUL-2016	14 70%	1251 49%	5 25%	517 20%	0 0%	57 2%	1 5%	784 30%	0 0%	1 0%
AUG-2016	20 59%	1305 49%	14 41%	533 20%	0 0%	55 2%	0 0%	774 29%	0 0%	1 0%
SEP-2016	19 63%	1364 50%	10 33%	545 20%	0 0%	53 2%	1 3%	781 29%	0 0%	1 0%
OCT-2016	15 94%	1412 51%	1 6%	561 20%	0 0%	53 2%	0 0%	777 28%	0 0%	1 0%
NOV-2016	18 72%	1452 52%	5 20%	580 21%	0 0%	53 2%	2 8%	756 27%	0 0%	1 0%
DEC-2016	9 75%	1479 52%	2 17%	587 21%	0 0%	53 2%	1 8%	762 27%	0 0%	1 0%
JAN-2017	13 81%	1518 53%	3 19%	587 20%	0 0%	52 2%	0 0%	756 26%	0 0%	1 0%
FEB-2017	14 78%	1560 54%	4 22%	588 20%	0 0%	48 2%	0 0%	732 25%	0 0%	1 0%
MAR-2017	13 87%	1620 55%	2 13%	602 20%	0 0%	49 2%	0 0%	732 25%	0 0%	1 0%
APR-2017	14 78%	1657 55%	4 22%	596 20%	0 0%	50 2%	0 0%	722 24%	0 0%	1 0%
MAY-2017	19 86%	1725 57%	3 14%	603 20%	0 0%	47 2%	0 0%	715 23%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2016	2285	32.78	1944	27.89	1609	23.08	158	2.27	61	0.88	913	13.10
FEB-2016	2279	32.61	1925	27.54	1668	23.87	153	2.19	59	0.84	905	12.95
MAR-2016	2266	32.39	1903	27.21	1706	24.39	154	2.20	61	0.87	905	12.94
APR-2016	2244	31.99	1894	27.00	1757	25.05	154	2.20	57	0.81	908	12.95
MAY-2016	2256	32.03	1887	26.79	1781	25.29	157	2.23	54	0.77	908	12.89
JUN-2016	2255	31.93	1877	26.58	1811	25.64	152	2.15	56	0.79	911	12.90
JUL-2016	2225	31.55	1865	26.45	1847	26.19	150	2.13	57	0.81	908	12.88
AUG-2016	2210	31.26	1839	26.01	1913	27.06	142	2.01	56	0.79	909	12.86
SEP-2016	2191	30.82	1831	25.76	1977	27.81	144	2.03	57	0.80	908	12.77
OCT-2016	2169	30.39	1829	25.62	2033	28.48	146	2.05	57	0.80	904	12.66
NOV-2016	2174	30.33	1817	25.35	2074	28.93	143	1.99	59	0.82	902	12.58
DEC-2016	2181	30.33	1808	25.14	2102	29.23	143	1.99	58	0.81	900	12.51
JAN-2017	2154	30.00	1793	24.97	2135	29.73	139	1.94	63	0.88	897	12.49
FEB-2017	2124	29.78	1772	24.84	2165	30.35	133	1.86	55	0.77	884	12.39
MAR-2017	2133	29.68	1755	24.42	2222	30.92	134	1.86	59	0.82	884	12.30
APR-2017	2109	29.37	1745	24.30	2260	31.47	133	1.85	59	0.82	876	12.20
MAY-2017	2107	29.16	1738	24.05	2309	31.95	133	1.84	59	0.82	880	12.18

Definitions:

n is number of participants on the specified regimen class in the specified month
 % is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2016	16	2	3	0	5	3	380
FEB-2016	18	4	0	6	3	5	331
MAR-2016	24	4	3	4	8	5	365
APR-2016	20	2	1	2	2	9	580
MAY-2016	23	2	1	3	4	13	510
JUN-2016	34	5	5	6	10	8	380
JUL-2016	25	2	6	6	3	7	320
AUG-2016	40	2	7	6	12	13	410
SEP-2016	27	8	2	6	4	4	253
OCT-2016	22	2	2	6	6	5	370
NOV-2016	27	3	4	5	7	8	390
DEC-2016	25	4	1	5	3	11	410
JAN-2017	22	3	2	3	6	6	390
FEB-2017	24	5	3	1	3	10	425
MAR-2017	19	5	3	5	2	2	220
APR-2017	21	1	2	6	5	6	360
MAY-2017	22	2	0	4	8	8	395

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2016	11049	3054
FEB-2016	11142	3135
MAR-2016	11202	3183
APR-2016	11249	3217
MAY-2016	11309	3266
JUN-2016	11365	3297
JUL-2016	11408	3332
AUG-2016	11453	3338
SEP-2016	11480	3342
OCT-2016	11511	3366
NOV-2016	11553	3387
DEC-2016	11583	3398
JAN-2017	11604	3419
FEB-2017	11631	3428
MAR-2017	11682	3477
APR-2017	11709	3493
MAY-2017	11751	3519

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
May 2017

N = 7226

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2017

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2017

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2017

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2017

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2017

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





**4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
INTERIOR Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	34	47	22
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	71	93	49	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	343	455	264	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	17
	35-49	*	*	36
	50+	*	*	82
Total HSDA:	175	233	135	
Total HA:		623	828	470

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	5	5	*
	20-34	64	65	*
	35-49	170	194	*
	50+	384	564	*
Total HA:		623	828	470

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	488	658	372
Female	135	170	98

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	470	54	580	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	*
	5 years or more	5	*
	<5 years	11	*
	Total HSDA:	34	22
KOOTENAY BOUNDARY	10 years or more	39	25
	5 years or more	19	16
	<5 years	13	8
	Total HSDA:	71	49
OKANAGAN	10 years or more	185	133
	5 years or more	78	64
	<5 years	80	67
	Total HSDA:	343	264
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	89	60
	5 years or more	41	38
	<5 years	45	37
	Total HSDA:	175	135
Total HA:		623	470

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	331	229
5 years or more	143	122
<5 years	149	119
Total HA:	623	470

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	37	53	14	23
KOOTENAY BOUNDARY	63	112	23	37
OKANAGAN	200	706	63	263
THOMPSON/CARIBOO/SHUSWAP	127	450	35	119
Total:	427	1321	135	442

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	88

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	5
	20-34	26	27	19
	35-49	108	119	80
	50+	191	258	148
	Total HSDA:	331	410	252
FRASER NORTH	0-19	14	14	*
	20-34	111	112	*
	35-49	345	385	*
	50+	500	787	*
	Total HSDA:	970	1298	756
FRASER SOUTH	0-19	11	11	7
	20-34	92	94	71
	35-49	375	427	313
	50+	455	672	376
	Total HSDA:	933	1204	767
Total HA:		2234	2912	1775

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	31	31	15
	20-34	229	233	175
	35-49	828	931	658
	50+	1146	1717	927
Total HA:		2234	2912	1775

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1701	2246	1375
Female	533	666	400

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1775	50	610	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	167	116
	5 years or more	95	83
	<5 years	69	53
	Total HSDA:	331	252
FRASER NORTH	10 years or more	479	345
	5 years or more	241	196
	<5 years	250	215
	Total HSDA:	970	756
FRASER SOUTH	10 years or more	440	348
	5 years or more	255	216
	<5 years	238	203
	Total HSDA:	933	767
Total HA:		2234	1775

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1086	809
	5 years or more	591	495
	<5 years	557	471
Total HA:		2234	1775

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	129	428	39	86
FRASER NORTH	237	1475	60	259
FRASER SOUTH	205	1223	45	346
Total:	571	3126	144	691

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	179
FRASER NORTH	639
FRASER SOUTH	513
Total:	1331

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	26
	35-49	*	*	67
	50+	*	*	186
	Total HSDA:		327	468
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		159	205
VANCOUVER	0-19	48	51	6
	20-34	449	459	352
	35-49	1498	1718	1102
	50+	2561	4301	1988
	Total HSDA:	4556	6529	3448
Total HA:		5042	7202	3858

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	52	55	7
	20-34	501	512	397
	35-49	1628	1865	1207
	50+	2861	4770	2247
Total HA:		5042	7202	3858

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4436	6329	3412
Female	604	871	446

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3858	52	620	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	167	132
	5 years or more	72	66
	<5 years	88	81
	Total HSDA:	327	279
RICHMOND	10 years or more	77	58
	5 years or more	41	34
	<5 years	41	39
	Total HSDA:	159	131
VANCOUVER	10 years or more	2386	1717
	5 years or more	1215	939
	<5 years	955	792
	Never on ART	0	0
	Total HSDA:	4556	3448
Total HA:	5042	3858	

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	2630	1907
	5 years or more	1328	1039
	<5 years	1084	912
	Never on ART	0	0
Total HA:		5042	3858

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	149	390	55	104
RICHMOND	42	271	14	97
VANCOUVER	556	10222	210	5335
Total:	747	10883	279	5536

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	106

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		296	415
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		113	150
SOUTH VANCOUVER ISLAND	0-19	5	5	*
	20-34	56	58	*
	35-49	199	234	*
	50+	429	661	*
	Total HSDA:		689	958
Total HA:		1098	1523	866

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	10	10	6
	20-34	96	101	70
	35-49	320	368	253
	50+	672	1044	537
Total HA:		1098	1523	866

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	890	1237	705
Female	208	286	161

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	866	53	490	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	140	114
	5 years or more	69	57
	<5 years	87	74
	Total HSDA:	296	245
NORTH VANCOUVER ISLAND	10 years or more	56	45
	5 years or more	30	25
	<5 years	27	20
	Total HSDA:	113	90
SOUTH VANCOUVER ISLAND	10 years or more	360	258
	5 years or more	169	138
	<5 years	160	135
	Total HSDA:	689	531
Total HA:		1098	866

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	556	417
	5 years or more	268	220
	<5 years	274	229
Total HA:		1098	866

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	177	788	79	210
NORTH VANCOUVER ISLAND	124	247	43	74
SOUTH VANCOUVER ISLAND	192	1611	42	544
Total:	493	2646	164	828

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	41
NORTH VANCOUVER ISLAND	30
SOUTH VANCOUVER ISLAND	96
Total:	167

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		40	48
NORTH WEST	0-19	*	*	0
	20-34	*	*	6
	35-49	*	*	20
	50+	*	*	24
	Total HSDA:		69	103
NORTHERN INTERIOR	0-19	7	7	*
	20-34	22	25	*
	35-49	76	92	*
	50+	82	133	*
	Total HSDA:		187	257
Total HA:		296	408	218

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	*
	20-34	33	40	*
	35-49	115	146	*
	50+	139	213	*
Total HA:		296	408	218

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	182	254	134
Female	114	154	84

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	218	49	565	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	16	7
	5 years or more	15	10
	<5 years	9	7
	Total HSDA:	40	24
NORTH WEST	10 years or more	20	10
	5 years or more	34	27
	<5 years	15	13
	Total HSDA:	69	50
NORTHERN INTERIOR	10 years or more	61	37
	5 years or more	63	57
	<5 years	63	50
	Total HSDA:	187	144
Total HA:		296	218

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	97	54
	5 years or more	112	94
	<5 years	87	70
Total HA:		296	218

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	33	59	7	11
NORTH WEST	66	149	20	30
NORTHERN INTERIOR	102	412	16	180
Total:	201	620	43	221

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	13
NORTHERN INTERIOR	22
Total:	41

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	*	10	*
	KOOTENAY BOUNDARY	*	7	*
	OKANAGAN	*	32	*
	THOMPSON/CARIBOO/SHUSWAP	*	40	*
	Total HA:	50	89	39
FRASER	FRASER EAST	31	40	24
	FRASER NORTH	52	84	43
	FRASER SOUTH	78	107	60
	Total HA:	161	231	127
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	25	46	22
	RICHMOND	9	14	8
	VANCOUVER	499	809	420
	Total HA:	533	869	450
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	52	78	44
	NORTH VANCOUVER ISLAND	14	23	13
	SOUTH VANCOUVER ISLAND	33	72	28
	Total HA:	99	173	85
NORTHERN	NORTH EAST	8	10	5
	NORTH WEST	33	58	25
	NORTHERN INTERIOR	68	101	59
	Total HA:	109	169	89
Total:		952	1531	790

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	592	977	486
Female	360	554	304

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	790	50	490	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicstat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicstat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Delavirdine (Rescriptor, DLV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from ViiV Healthcare.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Indinavir (Crixivan, IDV): a PROTEASE INHIBITOR from Merck.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.





Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

